The European Hematology Association (EHA) 2025 Annual Congress, the largest haematology event in Europe, will take place from 12 – 15 June in Milan, Italy. The meeting will bring together experts from across the globe to present the latest advances in haematological diseases, including myeloma.

Myeloma Patients Europe (MPE) will be attending the congress to keep the patient community informed about key developments in treatment and care. Throughout the event, MPE will share real-time updates via its social media channels (Facebook, LinkedIn, X and YouTube), including expert video interviews and key highlights from the scientific sessions.

MPE will also participate in various parts of the congress programme, including satellite symposia, the EHA Symposium on Patient Communications and poster sessions. Stay tuned for more updates during the event.

Key research in myeloma

The EHA 2025 scientific programme includes many abstracts on myeloma, covering both established therapies and new treatment approaches. While this article won’t summarise all relevant research, MPE believes the following presentations will be of greatest interest to patients:

• There will be some presentations focused on the role of minimal residual disease (MRD) in myeloma. In particular, the Phase III MIDAS trial which evaluates an MRD-guided approach following Isa-KRd (isatuximab, carfilzomib, lenalidomide, dexamethasone) induction in transplant-eligible patients. While not specific to myeloma, the EHA-EMA Joint Symposium will address the role of MRD in clinical and regulatory decision-making across all haematological malignancies. A panel of experts will explore the use and validity of this parameter in blood cancers.
• Some abstracts will look at the role of daratumumab in combination with other drugs to evaluate different scenarios in myeloma:
  • Elranatamab + daratumumab + lenalidomide (EDR): Early results from the Phase I MagnetisMM-6 study show the potential of EDR as frontline treatment for transplant-ineligible newly diagnosed patients.
  • Adding daratumumab to KRd (carfilzomib, lenalidomide, dexamethasone): The ADVANCE trial investigates the impact of combining daratumumab with KRd in newly diagnosed patients.
  • MRD-guided treatment decisions: The PREDATOR-MRD trial looks at whether daratumumab can delay disease progression when MRD reappears.
• High-risk and frontline therapy will also be addressed in new data presentations:
  • GMMG-CONCEPT trial: Final cohort results on Isa-KRd (isatuximab, carfilzomib, lenalidomide, dexamethasone) in transplant-eligible high-risk patients.
  • FORTE trial: Final results from this Phase III trial compare transplant vs non-transplant KRd-based strategies with maintenance in newly diagnosed patients.
• Several abstracts will focus on emerging treatments and combinations in relapsed/refractory myeloma:
  • Talquetamab (bispecific antibody)+ cetrelimab (monoclonal antibody): Initial safety and efficacy data from the Phase Ib TRIMM-3 study.
  • Anito-cel CAR T-cell therapy: Updated results from the IMMAGINE-1 Phase II trial assessing a novel CAR-T approach.
  • Linvoseltamab (bispecific antibody) + carfilzomib (proteasome inhibitor): Early data from the LINKER-MM2 trial testing this combination.
  • First-in-human trispecific antibody (JNJ-5322): A plenary abstract reveals promising early results of this next-generation antibody.
  • Long-term CARTITUDE-1 data: Five-year follow-up from the CAR-T treatment cilta-cel trial highlights deep and durable responses.
• New formulations and administration methods will also be discussed:
  • Isatuximab subcutaneous vs IV delivery: The IRAKLIA Phase III study compares subcutaneous (on-body) delivery to IV administration in combination with pomalidomide and dexamethasone.

MPE at EHA 2025

The MPE team will attend EHA 2025 to gather the most important updates on myeloma and other key advocacy topics such as access to treatment and quality of life for blood cancer patients. MPE will also participate in the following sessions:

• MPE Head of Patient Research, Eilidh Duncan, will provide the patient perspective on the panel “Navigating the waves: taking a holistic approach to managing Relapsed/Refractory Multiple Myeloma (RRMM)”, which will take place on Thursday, 12 June from 08:25 – 08:40 CEST in Brown Hall 3.
• MPE president Barbara Leonardi, will participate in the EHA Symposium on Patient Communications to discuss communication between healthcare professionals and patients about clinical trials. This session will be held on Thursday, 12 June from 17:00 – 18:15 CEST in Coral 1
• The MPE team, led by Eilidh Duncan, will present the results of the research “Myeloma patients’ attitudes and perceived burden towards treatment routes and locations: insights from a European survey”, in the poster session on Saturday, 14 June from 18:30 – 19:30 CEST at the Poster Hall.

With so much data being presented, EHA 2025 promises to be an exciting meeting for the myeloma community. MPE looks forward to sharing insights and analysis throughout and after the event.

Be sure to follow us on our channels for full coverage and don’t forget to register for our highlights webinar!